Hansen Medical's Magellan® Robotic System to Be Featured At 36th Annual Charing Cross International Symposium

MOUNTAIN VIEW, CA--(Marketwired - April 03, 2014) - Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in Intravascular Robotics, today announced it will exhibit its Magellan™ Robotic System at the 36th Annual Charing Cross International Symposium (CX 2014) from April 5 - 8 at Grand Hall Olympia in London, United Kingdom. The Company will be conducting product demonstrations and exhibiting the Magellan Robotic System at Booth 221.

In addition to these product demonstrations, multiple presentations discussing the Magellan Robotic System are also planned during the symposium. On Saturday, April 5 at 11:30am, five physicians (Alan Lumsden, M.D., Houston Methodist Hospital, Houston; Professor Jean-Pierre Becquemin, M.D., Henri Mondor Hospital, Cretéil, France; Thomas Nolte, M.D., Bad Bevensen Heart and Vascular Center, Germany ; Professor Nabil Chakfé, M.D., University Hospital Strasbourg, France; Professor Nicholas Cheshire, M.D., St. Mary's Hospital, London) will discuss their clinical experiences with Magellan in a symposium titled Clinical Experiences with Intravascular Robotics, during the "CX Vascular and Advanced Imaging Course" parallel session in the Grey Learning Centre.

On Sunday, April 6 at 3:20pm, Francis MacNamara, VP of Advanced Technology at Hansen Medical, has been invited to present a talk titled Robotic Endovascular Navigation: Latest Developments and New Technologies, during the "CX Innovation Showcase" parallel session.

"The Charing Cross International Symposium is one of the year's most important vascular conferences and we are pleased to have our Magellan System highlighted prominently in numerous settings throughout the conference," said Chris Lowe, Interim CEO of Hansen Medical. "The increasing level of activity around intravascular robotics at global, vascular conferences reflects the continuing momentum we are seeing with the Magellan System."

About the Magellan™ Robotic System
Hansen Medical's Magellan Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver improved predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedure types in centers across the U.S. and Europe.

The Magellan 9Fr Robotic Catheter allows for independent, robotic control of the distal tip of two telescoping catheters (an outer Guide and an inner Leader catheter), as well as robotic manipulation of standard guidewires. The Magellan 6Fr Robotic Catheter also provides independent robotic control of two separate bend sites on a single catheter, as well as robotic manipulation of standard guidewires. This smaller catheter design may be preferred by certain physicians who prefer a smaller diameter vessel incision site, or in procedures in smaller vessels.

About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is a global leader in Intravascular Robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, 9Fr Magellan™ Robotic Catheter, Magellan™ 6Fr Robotic Catheter, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan 9Fr Robotic Catheter has undergone both CE marking and 510(k) clearance and is commercially available in the European Union, and the U.S. The Magellan 6Fr Robotic Catheter has undergone 510(k) clearance in the U.S. and is in limited release for the next several months in anticipation of more wide-scale commercially availability later in 2014. In the European Union, the Company's Sensei® X Robotic Catheter System and Artisan® and Artisan Extend® Control Catheters are cleared for use during electrophysiology (EP) procedures, such as guiding catheters in the treatment of atrial fibrillation (AF), and the Lynx® Robotic Ablation Catheter is cleared for the treatment of AF. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the U.S., the Company's Sensei X Robotic Catheter System and Artisan and Artisan Extend Control Catheters are cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures. In the U.S., the Sensei X Robotic Catheter System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei X Robotic Catheter System and Artisan and Artisan Extend Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF, have not been established. Additional information can be found at www.hansenmedical.com.

Forward-Looking Statements
This press release contains forward-looking statements regarding, among other things, statements relating to goals, plans, objectives, milestones and future events. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements about the potential benefits, market size, timing and results of commercializing our Magellan 6Fr Robotic Catheter. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the uncertain timelines for the sales cycle for newly introduced products; the rate of adoption of our systems and the rate of use of our catheters; the scope and validity of intellectual property rights applicable to our products; competition from other companies; our ability to recruit and retain key personnel; our ability to manage expenses and cash flow, and obtain additional financing; and other risks more fully described in the "Risk Factors" section of our Annual Report on Form 10K for the year ended December 31, 2013 filed with the SEC on March 9, 2014 and the risks discussed in our other reports filed with the SEC. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart Design), Sensei and Lynx are registered trademarks, and Magellan and NorthStar are trademarks of Hansen Medical, Inc. in the United States and other countries.